After a initialon the news of the $175million offering the stock didbut has since rebounded and extended the gains and the momentum looks to continues with $25 as a reasonable short term target.Proceeds of the offering will go toward expanding development of ZW25 (as a single agent and in combination), expanding developing of ZW49 through an ongoing Phase 1 clinical trial and follow-on studies, for other novel preclinical programs and for general purposes.AVERAGE ANALYSTS PRICE TARGET $28.47AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHTCOMPANY PROFILEZymeworks,is a clinical-stage biopharmaceutical company, which engages in the, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford,Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.